Patent EP0251631A1 successfully refreshed from Google Patents.
EP0251631A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Interleukin-2 compositions
Assignee: Individual
•
Filing: 1987-06-22
•
Granted: —
•
Expires: 2007-06-22
Abstract
Abstract A biocompatible, biodegradable, bioerodible composite polymer matrix comprising interleukin-2 in an appropriate polymer. The polymer may be a polymer of copolymer of lactic acid, lactide, glycolide, glutamic acid, or it may be collagen or albumin. The material contains from 10² to 10⁸ U IL-2/g of polymer. Also disclosed is a method for making the composite polymer matrix and a method for implanting the material. A soft, malleable controlled-release composite material may be used for intracranial or other implantation and may be shaped or molded to fit the site from which the malignant tissue has been removed, opposing the residual tumor, complementing hemostasis, compatible with anatomical structure, and functioning as an implantable immunotherapeutic adjuvant.
Inventors
- 👤 Mark E. Anderson, M.D.
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 18:10
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5031
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
10 words
A composition comprising interleukin-2 and a physiologically acceptable, bioerodible polymer.
Claim 2
Dependent Claim
10 words
A composition comprising interleukin-2 and a physiologically acceptable, bioerodible polymer.
Claim 3
Dependent Claim
29 words
A composition as claimed in Claim 1, wherein the polymer comprises at least one polymer or copolymer of one or more of lactic acid, glycolide, lactide, and glutamic acid.
Claim 4
Dependent Claim
10 words
A composition as claimed in Claim 1 in particulate form.
Claim 5
Dependent Claim
26 words
A composition as claimed in Claim 1 in the form of a shaped article, wherein the average molecular weight of said polymer is at least 5,000.
Claim 6
Dependent Claim
25 words
A composition as claimed in Claim 1 in the form of a malleable material, wherein said polymer has an average molecular weight less than 5,000.
Claim 7
Dependent Claim
22 words
A composition as claimed in any of Claims 1-5, comprising from about 10² to about 10⁸ U interleukin-2 per g of polymer.
Claim 8
Dependent Claim
22 words
A composition as claimed in any of Claims 1-5, comprising from about 10⁴ to about 10⁶ U interleukin-2 per g of polymer.
Claim 9
Dependent Claim
13 words
A composition as claimed in Claim 1, comprising interleukin-2 microencapsulated in said polymer.
Claim 10
Dependent Claim
20 words
A composition as claimed in Claim 1, comprising an open cell foam impregnated with interleukin-2 and encased in said polymer.
Claim 11
Independent Claim
32 words
A method for making a controlled release polymer containing interleukin-2, said method comprising combining interleukin-2 and at least one bioerodible polymer to form an intimate mixture of said interleukin-2 in said polymer.
Claim 12
Independent Claim
32 words
A method for making a controlled release polymer containing interleukin-2, said method comprising combining interleukin-2 and at least one bioerodible polymer to form an intimate mixture of said interleukin-2 in said polymer.
Claim 13
Dependent Claim
63 words
A method as claimed in Claim 10, wherein said polymer is a physiologically acceptable, bioerodible organic polymer and said method further comprises dissolving said polymer in a solvent to make a solution; mixing interleukin-2 with said solution to form a dispersion; and precipitating a composite material from said dispersion, wherein said composite material comprises said bioerodible polymer in intimate admixture with said interleukin-2.
Claim 14
Dependent Claim
24 words
A method as claimed in Claim 11, wherein the composite material comprises from about 10² to about 10⁸ U interleukin-2 per g of polymer.
Claim 15
Independent Claim
38 words
A method as claimed in any of Claims 10, 11 or 12 wherein said polymer has an average molecular weight of at least 5,000, further comprising the step of forming said precipitated composite material into a shaped article.
Claim 16
Dependent Claim
23 words
A method as claimed in Claim 11 or 12, further comprising the step of forming said precipitated composite material into a particulate material.
Claim 17
Dependent Claim
43 words
A method as claimed in Claim 10, wherein said polymer is a malleable biocompatible, bioerodible polymer having an average molecular weight less than 5000; and said mixture is formed by mechanically dispersing interleukin-2 in said polymer to form a controlled-release polymer containing interleukin-2.
Claim 18
Dependent Claim
15 words
A method as claimed in Claim 10 or 15, wherein said polymer is polylactic acid.
Claim 19
Dependent Claim
41 words
A method as claimed in Claim 15 or 16, wherein said dispersing step comprises: dissolving said polymer in a solvent to obtain a solution; dispersing said interleukin-2 in said solution to form a dispersion; and removing said solvent from said dispersion.
Claim 20
Independent Claim
31 words
A method for making a controlled release interleukin-2 composition, comprising the steps of: preparing particles of interleukin-2 in a pharmaceutically-acceptable diluent; and encapsulating said particles in a bioerodible , physiologically-acceptable polymer.
Claim 21
Independent Claim
31 words
A method for making a controlled release interleukin-2 composition, comprising the steps of: preparing particles of interleukin-2 in a pharmaceutically-acceptable diluent; and encapsulating said particles in a bioerodible , physiologically-acceptable polymer.
Claim 22
Dependent Claim
23 words
A method as claimed in Claim 18, wherein said polymer is a polymer or copolymer of lactic acid, glycolide, lactide, or glutamic acid.
Claim 23
Dependent Claim
13 words
A method as claimed in Claim 18, wherein said encapsulating step comprises microencapsulation.
Claim 24
Dependent Claim
16 words
Use of a composition as claimed in any of Claims 1-9 for the treatment of tumors.
Claim 25
Dependent Claim
16 words
Use of a composition as claimed in any of Claims 1-9 for treatment of malignant glioblastoma.
Claim 26
Dependent Claim
22 words
Use of a composition as claimed in any of Claims 1-9 for the manufacture of a medicament for the treatment of tumors.
References Cited (Backward Citations)
GB2121053A
Cited
EP0139286A2
Cited
EP0140255A2
Cited
EP0145240A2
Cited
EP0154316A2
Cited
EP0158487A2
Cited
DE3536902A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.